Despite controversy about whether cerebral arteriosclerosis is a valid clinical entity and independent of senile dementia and/or â€˜¿ func tional' senile psychoses (Post, i 97 I ), there is a good reason for differentiating it in clinical practice, and its incidence is increasing (Registrar General, 1960). Twenty-four such patients were treated for twelve months with randomly allocated placebo and cyclandelate 400 mg. four times daily.
.There is, however, no invariable improvement in ischae mic brain damage when cerebral blood flow is increased (Eichhorn, 1965), and indeed there may even be a paradoxical effect. The course of cerebrovascular disease in the individual patient is moreover extremely unpredictable; indeed, diagnostically so. Adequate assessment of possi ble efficacy of treatment therefore presents not only the usual pitfalls of drug trials in terms of adequate controls etc., but also the problems of the possible wide divergence between physio logical and clinical improvement in this parti cular condition (Eichhorn, 1965) , as well as difficulties in its diagnosis and uncertainties due to its marked tendency to spontaneous remission and variability in clinical course. We have tried to avoid some, at least, of these hazards which have bedevilled much previous work.
METHODOLOGY
Patients were selected for the trial if they showed objective signs of dementia of at least No significant difference in the use of psycho tropic or other drugs was found between placebo and treatment groups.
The behavioural scales were not analysed, as patients showed insufficient variance on these scales during the course of the trial for this to be meaningful.
The analysis of data for the memory tests falls short ofstatistical significance (p < o .075), A previous study (Hall and Harcup, 1969) 
